Wells Fargo upgraded Travere Therapeutics (TVTX) to Overweight from Equal Weight with a price target of $27, up from $9.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics, CSL Vifor announce Swissmedic approval of FILSPARI
- Travere reports Swissmedic grants temporary marketing authorization for Filspari
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
- Travere Therapeutics initiated with an Outperform at Scotiabank
- Travere Therapeutics price target raised to $30 from $12 at Evercore ISI